Overview of Cancer Vaccines

Copier, John; Dalgleish, Angus

doi:10.1002/9783527625970.ch16

Cited by 1 publication

(3 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Least-squares methods were used to determine the permeation profile . The skin permeation partition coefficient from the donor phase to the receiver phase through the SC ( K SC ) and the diffusion coefficient through the SC ( D SC ) were calculated using the following flow equations: K SC = ( Jl )/( D SC × C d ) and D SC = l SC /6 t d , respectively. Here, l SC represents the thickness of the skin layer, t d is the lag time, J is the transdermal flux, and C d is the drug concentration in the tested formulations.…”

Section: Experimental Methodologymentioning

confidence: 99%

“…After tumor development, the tumor volume and body weight were measured at 1 day intervals using slide calipers and a weighing scale. The tumor volume was calculated up to the point when it exceeded 10,000 mm 3 using the following equation: tumor volume [mm 3 ] = (length [mm]) × (width [mm]) × 0.5. When the volume of the tumor exceeded 2500 mm 3 , the mouse was considered clinically dead …”

Section: Experimental Methodologymentioning

confidence: 99%

“…Cancer immunotherapy has become an attractive clinical strategy for cancer treatment because it has higher specificity and antitumor immune responses with minimal side effects than conventional chemotherapies, such as intravenous, oral, arterial, peritoneal, abdominal, and injected therapies. − Injection is the most frequently used method of delivery of immunotherapy designed to stimulate a specific immune response. However, injection has several demerits, including poor patient compliance, pain, needle phobia, and needlestick injury .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transdermal Delivery of Antigenic Protein Using Ionic Liquid-Based Nanocarriers for Tumor Immunotherapy

Uddin

Islam

Moshikur

et al. 2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Transdermal drug delivery systems (TDDSs) may be useful for preventing various diseases including cancer. However, the stratum corneum (SC) inhibits the permeation of foreign particles into the skin. To obtain an effective TDDS, we developed a protein-containing nanocarrier (PCNC) comprising an antigenic protein (ovalbumin/OVA) stabilized by a combination of surfactants, i.e., a lipid-based surface-active ionic liquid and Tween-80. The PCNC was lyophilized to remove water and cyclohexane and then dispersed in isopropyl myristate. It is biocompatible both in vitro and in vivo, and is suitable for use in a therapeutic TDDS. The skin permeability of the PCNC was significantly (p < 0.0001) enhanced, and the transdermal distribution and transdermal flux of the OVA delivery system were 25 and 28 times greater, respectively, than those of its aqueous formulation. The PCNC disrupted the order of lipid orientation in the skin’s SC and increased intercellular protein delivery. It demonstrated effective antitumor activity, drastically (p < 0.001) suppressed tumor growth, increased mouse survival rates, and significantly (p < 0.001) stimulated the OVA-specific tumor immune response. The PCNC also increased the number of cytotoxic T cells expressing CD8 antibodies on their surfaces (CD8 + T-cells) in the tumor microenvironment. These findings suggest that PCNCs may be promising biocompatible carriers for transdermal antigenic protein delivery in tumor immunotherapy.

show abstract

Section: Experimental Methodologymentioning

confidence: 99%

Section: Experimental Methodologymentioning

confidence: 99%